Injectable weight-loss drugs such as Ozempic have exploded in popularity over the past few years, yet scientists are still exploring how they affect our bodies.
In 2024, around 5 per cent of Britons had used an injectable glucagon-like peptide-1 (GLP-1) receptor agonist, a medication known under brand names such as Wegovy, Ozempic and Mounjaro. The drugs work by mimicking the hormone GLP-1 to slow down digestion and lower appetite, which can lead to significant weight loss.
